Navigation Links
Neurologix Presents One-Year Follow-Up Data From Phase 2 Study of NLX-P101 in Parkinson's Disease at International Neuromodulation Society 10th World Congress
Date:5/26/2011

.

"The results presented today at the INS World Congress add to a growing body of clinical evidence demonstrating that our novel gene therapy approach may provide significant clinical benefits to Parkinson's disease patients," During added. "In the treatment arm of the Phase 2 study, improved motor control was seen at one month, continued virtually unchanged throughout the six-month blinded study period and persisted through 12 months of follow-up. This suggests that the treatment effect from NLX-P101 is meaningful and durable over the long-term."

Drs. During and Kaplitt have been at the forefront of gene therapy research since 1989 and the Phase 2 trial was the culmination of nearly 20 years of progress with their work in gene transfer technology using an adeno-associated virus (AAV) vector (a disabled, non-pathogenic virus). They were the first to demonstrate that AAV could be an effective gene therapy agent in the brain, which they reported in their landmark Nature Genetics paper in 1994. Drs. During, Kaplitt and colleagues subsequently published additional research demonstrating the beneficial effects of AAV-GAD gene therapy for PD in the journal Science in 2002.

About the Phase 2 Study

The trial involved 45 subjects with moderate to advanced PD who were not adequately controlled with current therapies. Medical centers that participated in the study included: Henry Ford Health System; Massachusetts General Hospital; Stanford University School of Medicine; The Feinstein Institute for Medical Research of the North Shore-LIJ Health System; The Ohio State University College of Medicine; University of Colorado School of Medicine; University of Rochester School of Medicine; and Wake Forest University School of Medicine.

Study subjects were randomized to receive either NLX-P101 treatment or sham surgery. Subjects in the NLX-P101 treatment arm received infusions of the genetic material directly into bilateral subt
'/>"/>

SOURCE Neurologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference
2. Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the 30th ASBMR Annual Meeting
3. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
4. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
5. GeoVax Presents Data at AIDS Vaccine 2008 Conference
6. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
7. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
8. Northern Antibiotics Presents New Data on Novel Polymyxin Compounds at the Joint ICAAC/IDSA 2008
9. Sangamo BioSciences Presents Data at ICAAC Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
10. Prominent Urologist Dr. David B. Samadi Presents Breakthrough Robotic Surgery Techniques on OR Live Webcast
11. AmeriCares Presents Power of Partnership Award to Baxter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... have succeeded in measuring vibrational motion of a single ... how vibration of a single molecule differs from the ... was performed at the University of California, Irvine, where ... works as a visiting fellow under professor Vartkess A. ... team was lead by Professor Eric O. Potma. The ...
(Date:8/20/2014)... Francisco, CA (PRWEB) August 20, 2014 ... Conference is being held on October 29-30 in ... perspectives from industry, academic and government researchers and clinicians ... in the space. , In the twelve years ... one hundred therapies have been introduced with pharmacogenetic information ...
(Date:8/20/2014)... GraphDB™ 6.0 from ... to the enterprise replication cluster, faster loading speeds, ... and Elasticsearch. This release happens to coincide with ... – GraphDB™ was formerly known as OWLIM. ... mature enterprise resilient RDF triplestore will also benefit ...
(Date:8/19/2014)... 19, 2014 Cellgen Diagnostics ... $200,000 to fund a corporate lab for its ... This development is a critical component in the ... to the implementation of personalized medicine – a ... medicine. , Indiegogo contributions will support Cellgen’s intent ...
Breaking Biology Technology:Seeing a molecule breathe 26th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3
... Calif., Oct. 5 Bionovo, Inc.,(Nasdaq: BNVI ), a ... in the areas of women,s health and cancer, today announced,that ... at the 4th,Annual BIO Investor Forum. The presentation will ... the Palace Hotel in San Francisco, CA. A live ...
... Cerimon,Pharmaceuticals, Inc., today announced Paul Sekhri, Cerimon,s ... 2007 BIO Investor Forum on,Thursday, October 11, 2007, ... in San,Francisco. The presentation will take place in ... Cerimon Pharmaceuticals, Inc. is a biopharmaceutical company ...
... Coalition for a,Competitive Pharmaceutical Market (CCPM) issued the ... announcement regarding its,"Generic Initiative for Value and Efficiency" ... grappling with,how to manage escalating prescription drug costs, ... focus on ways to enhance timely generic access.,Today,s ...
Cached Biology Technology:CCPM Issues Statement on FDA's GIVE Initiative 2
(Date:8/19/2014)... Aug. 19, 2014 To improve students, chances ... grades, the University of Houston (UH) implemented a ... students at risk for failure. , Through ... Board (THECB), the Department of Biology and Biochemistry ... students taking "General Biology" for non-majors and "Introductory ...
(Date:8/19/2014)... of the world, leprosy and tuberculosis live side-by-side. ... leprosy per year, with nearly all of them ... century-old vaccine Bacille Calmette-Guerin, or BCG, provides only ... a more potent vaccine is needed to combat ... stronger weapon against both diseases., In a study ...
(Date:8/19/2014)... Aug. 19, 2014 ) -- Scientists at the Houston ... up and transfer single cells using a pipette -- ... describe this engineering feat and preliminary test results in ... American Chemical Society . , "Studying single cells and ... biomedical research," said nanomedicine department. faculty member Lidong Qin, ...
Breaking Biology News(10 mins):University of Houson program earns kudos for improving grades, retaining students 2University of Houson program earns kudos for improving grades, retaining students 3New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2Moving single cells around -- accurately and cheaply 2
... century, scientists have struggled with plutonium contamination spreading further ... in humans and animals. It was known nanometer ... no one had been able to study its structure ... groundwater. Scientists at the U.S. Department of ...
... Spanish flu outbreak of 1918 killed between 30 and ... cause of death was acute respiratory distress syndrome (ARDS). ... body during which the lung becomes severely damaged. ARDS ... but also by chemical agents. These could be toxic ...
... the most common cause of episodic headache, and by ... visit. It affects some 15% of the population, including ... considerable burden on healthcare in both the developed and ... years, great strides have been made in discovering common ...
Cached Biology News:Scientists discover how nanocluster contaminants increase risk of spreading 2New strategies against bird flu 2Concentrating on different aspects of pain leads to breakthrough in migraine genetics 2
... CrysScreen is a software package that ... interface for custom buffer creation, set-up ... in crystallization trials. The software helps ... in automated protein crystallography: ...
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
Mouse monoclonal [H4B4] to LAMP2 - Lysosome Marker (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 3920 SwissProtID: P13473...
... Nikon's NIS-Elements revolutionizes imaging software ... automated intelligence to microscopes, cameras, components ... visualization and achiving tools. Its intuitive ... image acquisition times while providing powerful ...
Biology Products: